20050-U
ORBO™ 608 Amberlite™ XAD®-2 (20/50) 150/75 mg
W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea
Synonym(s):
ORBO™ Amberlite™ XAD-2 Tube
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
NACRES:
NB.24
UNSPSC Code:
12190000
material
W,W,W separators
agency
NIOSH 2514,2543,5514
product line
Amberlite™, ORBO™
composition
Bed A, 150 mg , Bed B, 75 mg
packaging
pkg of 50 ea
manufacturer/tradename
ORBO™ 608
technique(s)
active air sampling: suitable
O.D. × L
8 mm × 110 mm
matrix
XAD-2
particle size
20-50 mesh
application(s)
air monitoring
environmental
industrial hygiene
General description
ORBO sorbent tubes (W,W,W separators, O.D. × L 8 mm × 110 mm) contain two beds of the same selective adsorbent separated by glass wool or foam, for gas and vapor sampling. The dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.
Legal Information
Amberlite is a trademark of DuPont de Nemours, Inc.
ORBO is a trademark of Sigma-Aldrich Co. LLC
XAD is a registered trademark of The Dow Chemical Company or an affiliated company of Dow
Storage Class
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
A Orbo et al.
Gynecologic oncology, 52(3), 320-325 (1994-03-01)
Several studies have shown altered biokinetics of cyclic nucleotides in human cancer. In order to mimic the growing tumor bulk in carcinomas of the uterine cervix, four human cell lines (C4-I, C33A, ME-180, and SiHa) were expanded in serum-supplemented cell
A Orbo et al.
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 972-976 (1997-03-10)
The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancers in the endometrium, cervix, ovarium, and mammary glands.
Bjørn T Moe et al.
Anticancer research, 29(4), 1047-1052 (2009-05-06)
Endometrial hyperplasia is a precursor lesion of endometrial carcinoma. Clinical studies of endometrial hyperplasia have shown that levonorgestrel (LNG) is more therapeutically effective than medroxyprogesterone acetate (MPA). The present pharmacological in vitro study was performed to compare progestin effects on
K Flo et al.
Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)
Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed
A Ørbo et al.
BJOG : an international journal of obstetrics and gynaecology, 123(9), 1512-1519 (2015-12-03)
To investigate relapse rates after the successful treatment of patients with non-atypical endometrial hyperplasia who were randomised to either a levonorgestrel-impregnated intrauterine system (LNG-IUS; Mirena(®) ) or two regimens of oral medroxyprogesterone acetate (MPA) after primary histological response. A multicentre
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service